Table 1.
Baseline characteristics in patients according to dichotomized Y/X ratio
| Total (n = 362) | LOY ≤17% (n = 255) | LOY >17% (n = 107) | |
|---|---|---|---|
| Available | |||
| Male sex | 362 | 255 (100.00) | 107 (100.00) |
| Age (years) | 362 | 81 (77–85) | 83 (80–85) |
| BMI (kg/m2) | 362 | 26.57 (24.55–29.71) | 25.88 (24.14–28.25) |
| CVD | 362 | 61 (23.92) | 21 (19.63) |
| PAOD | 362 | 37 (14.51) | 18 (16.82) |
| Prior heart surgery | 362 | 39 (15.29) | 12 (11.21) |
| COPD | 361 | 41 (16.08) | 17 (15.89) |
| Diabetes | 362 | 85 (33.33) | 28 (26.17) |
| Hypertension | 362 | 209 (81.96) | 82 (76.64) |
| NYHA class | 362 | ||
| ȃI | 6 (2.35) | 0 (0.00) | |
| ȃII | 52 (20.39) | 21 (19.63) | |
| ȃIII | 179 (70.20) | 79 (73.83) | |
| ȃIV | 18 (7.06) | 7 (6.54) | |
| MI | 362 | 57 (22.35) | 21 (19.63) |
| Stroke | 362 | 33 (12.94) | 10 (9.35) |
| TIA | 362 | 8 (3.14) | 4 (3.74) |
| PCI | 362 | 121 (47.45) | 48 (44.86) |
| CAD | 362 | ||
| ȃ0 | 75 (29.41) | 30 (28.04) | |
| ȃ1 | 66 (25.88) | 25 (23.36) | |
| ȃ2 | 44 (17.25) | 18 (16.82) | |
| ȃ3 | 70 (27.45) | 34 (31.78) | |
| ȃPPM | 362 | 39 (15.29) | 17 (15.89) |
| ȃAF | 362 | 98 (38.43) | 52 (48.60) |
| ȃLVEF (%) | 355 | 55 (40–60) | 55 (40–60) |
| EuroSCORE II | 362 | 3.66 (2.04–6.26) | 3.66 (2.10–6.83) |
| DNMT3A/TET2-CHIP | 345 | 73 (30.3) | 28 (26.9) |
Values are given as n (%), or median (interquartile range).
AF, atrial fibrillation; BMI, body mass index; CAD, coronary artery disease; CHIP, clonal hematopoiesis of indeterminate potential; COPD, chronic obstructive pulmonary disease; CVD, cerebrovascular disease; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NYHA, New York Heart Association; PAOD, peripheral arterial occlusive disease; PCI, percutaneous coronary intervention; PPM, permanent pacemaker implantation; TIA, transient ischemic attack.